Filter by
Date
Cancer type
Cancer stage
Biomarker
Method of analysis
Selected categories
January 2025
DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients
ANGLE Europe Limited, Guildford, UK, published at the 8th Annual DDR Inhibitors Summit 2025
December 2024
SABCS: A novel, semi-automated Pipeline for HER2 Quantification on CTCs in breast cancer patients. Is cytopathology of peripheral blood a new diagnostic option?
AACR LBx 24 – Development of a scoring system to classify HER2 protein expression in Circulating Tumour Cells through immunofluorescence following isolation using Parsortix® instruments
ANGLE Europe Limited, Guildford, UK, Published at the AACR LBx Conference 2024
AACR LBx 24 – Investigating PD-L1 status in Circulating Tumour Cells isolated from the blood samples of lung cancer patients
EACR LBx 24 – Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour Cell Analysis Using Amplitude-Based Methodology
ANGLE Europe Limited, Guildford, UK, Published at the EACR LBx Conference 2024
EACR LBx 24 – Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples.
ANGLE Europe Limited, Guildford, UK, Published at the EACR LBx Conference 2024
1 23 ... 10